PetMedix™ is pleased to announce a collaboration with Zoetis to develop novel, fully species-specific companion animal monoclonal antibody therapeutics (mAbs) using PetMedix’s proprietary transgenic platforms. As part of the collaboration, PetMedix will undertake discovery activities against a number of key targets, and Zoetis has an exclusive option to develop and bring these therapies to market.
Having brought three novel mAbs to market to date, Zoetis is a leader in companion animal antibody therapeutics, including fully species-specific antibodies. Their end-to-end research and development expertise in veterinary antibody therapeutics coupled with their manufacturing, sales and marketing scale and success makes them a strong partner for PetMedix. This is well complemented by PetMedix’s strengths in antibody discovery, thanks to the combination of its proprietary transgenic platforms and its team of nearly 50 world-class scientists at its labs in Cambridge, UK.
To learn more about the collaboration, see the full article here.